Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer.

Abstract

Colorectal cancer (CRC) is the most lethal gastrointestinal cancer in both males and females worldwide (Sung et al., 2021). Because of the high heterogeneity of tumors, robust prognostic biomarkers are urgently needed in CRC management (Koncina et al., 2020). Chemokine signaling is a well-known pivotal player in immunity, inflammation, and cancer metastasis (Lacalle et al., 2017; Poeta et al., 2019; Do et al., 2020), and multiple genes involved in chemokine signaling have been demonstrated as potential prognostic biomarkers for CRC (Cabrero-De Las Heras and Martínez-Balibrea, 2018; Ottaiano et al., 2020; Yu et al., 2020). Therefore, the aim of our study was to develop a chemokine signaling-based multigene signature (CSbMgSig) that could effectively predict overall survival (OS) and therapeutic response for patients with CRC.

• Authors: Xin Qi, Donghui Yan, Jiachen Zuo, Rui Wang, Jiajia Chen
• Journal: Journal of Zhejiang University. Science. B (J Zhejiang Univ Sci B) Vol. 22 Issue 12 Pg. 1053-1059 (Dec 15 2021) ISSN: 1862-1783 [Electronic] China
• PMID: 34904417 (Publication Type: Journal Article)

Chemical References

• Chemokines

Topics

• Adult
• Aged
• Chemokines (genetics)
• Colorectal Neoplasms (genetics, immunology, mortality, therapy)
• Female
• Gene Expression Regulation, Neoplastic
• Humans
• Male
• Middle Aged
• Neoplasm Staging
• Prognosis